Regulus Therapeutics (NASDAQ:RGLS) Upgraded by Wall Street Zen to "Hold" Rating

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a research note issued on Friday.

Several other brokerages have also commented on RGLS. Wells Fargo & Company reissued an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a report on Thursday, May 1st. Leerink Partners reissued a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Leerink Partnrs downgraded Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Canaccord Genuity Group restated a "hold" rating and issued a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, March 14th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Regulus Therapeutics has a consensus rating of "Hold" and a consensus target price of $8.50.

Regulus Therapeutics Price Performance

RGLS remained flat at $8.16 during trading on Friday. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.35. The business has a fifty day simple moving average of $7.39 and a two-hundred day simple moving average of $3.52. The company has a market cap of $564.92 million, a PE ratio of -11.18 and a beta of 0.35.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. Analysts predict that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Regulus Therapeutics

In related news, insider Preston Klassen acquired 12,000 shares of Regulus Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $7.99 per share, for a total transaction of $95,880.00. Following the completion of the transaction, the insider owned 48,055 shares in the company, valued at $383,959.45. This represents a 33.28% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regulus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Regulus Therapeutics by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock worth $67,000 after buying an additional 1,644 shares in the last quarter. PEAK6 LLC purchased a new position in Regulus Therapeutics during the fourth quarter worth approximately $95,000. Oppenheimer & Co. Inc. purchased a new position in Regulus Therapeutics during the first quarter worth approximately $96,000. Velan Capital Investment Management LP purchased a new position in Regulus Therapeutics during the fourth quarter worth approximately $111,000. Finally, AQR Capital Management LLC purchased a new position in Regulus Therapeutics during the first quarter worth approximately $120,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.